Cryoneurolysis for TKA - a Pilot Study
Primary Purpose
Knee Pain Chronic, Osteoarthritis
Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Iovera - Cryoneurolysis
Local anesthetic
Sponsored by
About this trial
This is an interventional treatment trial for Knee Pain Chronic focused on measuring total knee artroplasty, knee replacement
Eligibility Criteria
Inclusion Criteria:
- Male and female patients
- 18 to 80 years of age
- Patients with radiographic confirmation and clinical correlation for severe osteoarthritis diagnosis with an indication for total knee replacement
- Patients undergoing primary unilateral total knee replacement
- No previous unilateral knee injection (steroids/biologics) within 6 months of study
- The patient is able to read and understand English and provide informed consent to participation in the study
Exclusion Criteria:
- Pregnancy and breastfeeding
- Cryoglobulinemia
- Paroxysmal cold hemoglobinuria
- Cold urticaria
- Raynaud's disease
- Current Opioid use
- History of opiate, narcotic and alcohol abuse
- Revision total knee replacement surgery
- Open and/or infected wounds at or near the affected knee
Sites / Locations
- St Michael's HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Iovera
Placebo
Arm Description
Cryoneurolysis + standard of care: Usual intervention plus pre-operation Iovera treatment. Patients will receive local anaesthesia unilaterally to the affected knee prior to the treatment and then the anesthesiologist will administer the freezing cold therapy (Iovera device) to the affected knee.
Placebo: Usual intervention plus pre-operation placebo. The placebo group will receive short-acting local anaesthesia injection unilaterally to the affected knee.
Outcomes
Primary Outcome Measures
Patient recruitment rate
The primary objective of the pilot trial is to establish the feasibility of a larger definitive trial by successfully recruiting 20 patients over a 12-month period.
Secondary Outcome Measures
Opioid consumption
Cumulative opioid consumption will be assessed by drug diaries that patients will bring back to the hospital visit at 2 week follow up appointment.
Numeric Rating Scale of Pain
It consists of 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme.
Oxford Knee score
is a validated 12-item patient-reported outcome specifically designed and developed to assess function and pain after total knee replacement surgery. It scores from 0 (might indicate severe arthritis) to 48 (normal joint function).
EQ-5D-5L
It is a health-related quality of life measure that consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ-VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The EQ-VAS records the patient's self-rated health on a vertical visual analogue scale.
Quality of Recovery
The 15-item Quality of Recovery (QoR-15) scale is a validated, simple, reliable, multidimensional questionnaire that measures the quality of recovery after surgery. Fifteen questions assess five domains of patient-reported health status: pain, physical comfort, physical independence, psychological support and emotional state.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05286996
Brief Title
Cryoneurolysis for TKA - a Pilot Study
Official Title
Cryoneurolysis for Pain Management After Total Knee Arthroplasty - a Pilot Study
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2022 (Actual)
Primary Completion Date
October 1, 2023 (Anticipated)
Study Completion Date
December 1, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Unity Health Toronto
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Total Knee Arthroplasty (TKA) is also known as a knee replacement. It is one of the most common orthopaedic (bone) surgeries performed and is usually very successful, but some people who have had a knee replacement feel pain that lasts for at least 3 months after surgery and thus continue to take pain control/ analgesic (opioids) medication. Opiates are medications like morphine.
Pain post-surgery can make it difficult to recover and return to daily activities. A better control of pain before the surgery, can help people feel less pain, recover faster, and use less opioids after surgery.
Cryoneurolysis means freezing the nerves that can cause pain. It uses very low temperatures in a specific body part (e.g., nerves to the knee) to freeze the pain nerves and therefore reduce the pain. When applied before the surgery it might help with postoperative pain after knee replacement.
This study will evaluate Iovera, a cryoneurolysis handheld device commercially available in Canada that delivers freezing cold to a target nerve by using nitrous oxide. Cryoneurolysis can relieve pain and symptoms associated with osteoarthritis of the knee for up to 90 days.
Detailed Description
Patients undergoing total knee replacement (TKA) often experience a significant amount of pain during the immediate postoperative period, thus appropriate pain management before, during and after the surgery is a key component of patient satisfaction and better outcomes.
Opioids are the most commonly prescribed drugs to manage postoperative orthopaedic pain; however, their well-known side effects, such as nausea, vomiting and the potential high risk for dependence, can slow down recovery and lead to substance disorders.
Studies have reported, that more than 20% of patients receiving TKA experience persistent and unchanged pain post-surgery. Moreover, 15 to 25% of TKA patients continue the use of opioids at 3 months after surgery, 35% of patients report pain that interferes with their activities of daily living 4 months after surgery.
Adequate pain management before the surgery may prevent or reduce the rate of persistent pain and opioid usage after TKA. Cryoneurolysis is a minimally invasive procedure that uses a small probe to freeze [at very low temperatures - below -20oC] the target nerve. It can promote regeneration of the structure and function of the affected nerve. It has shown promising short and long-term results in a variety of acute and chronic pain conditions.
Retrospective studies revealed that preoperative cryoneurolysis might be efficacious in attenuating pain improving function and reducing opioid prescription 12 weeks after TKA. However, the studies are mostly retrospective, with small numbers of patients and not standardized knee specific outcomes.
This is a pilot randomized clinical trial to establish the feasibility of administering the study device (Iovera) to our target population as well as to test and refine the recruitment criteria, study design, patient acceptability, and operational strategies for use in a large definitive study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Knee Pain Chronic, Osteoarthritis
Keywords
total knee artroplasty, knee replacement
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Parallel-randomized participant-blinded control trial
Masking
ParticipantOutcomes Assessor
Masking Description
Participants and outcomes assessors will be blinded about treatment allocation.
Allocation
Randomized
Enrollment
20 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Iovera
Arm Type
Experimental
Arm Description
Cryoneurolysis + standard of care: Usual intervention plus pre-operation Iovera treatment. Patients will receive local anaesthesia unilaterally to the affected knee prior to the treatment and then the anesthesiologist will administer the freezing cold therapy (Iovera device) to the affected knee.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo: Usual intervention plus pre-operation placebo. The placebo group will receive short-acting local anaesthesia injection unilaterally to the affected knee.
Intervention Type
Device
Intervention Name(s)
Iovera - Cryoneurolysis
Intervention Description
Iovera system delivers precise, controlled doses of cold temperature only to the targeted nerve through a handheld device.
Intervention Type
Drug
Intervention Name(s)
Local anesthetic
Other Intervention Name(s)
Placebo
Intervention Description
Placebo - local anaesthesia
Primary Outcome Measure Information:
Title
Patient recruitment rate
Description
The primary objective of the pilot trial is to establish the feasibility of a larger definitive trial by successfully recruiting 20 patients over a 12-month period.
Time Frame
12 months postoperative
Secondary Outcome Measure Information:
Title
Opioid consumption
Description
Cumulative opioid consumption will be assessed by drug diaries that patients will bring back to the hospital visit at 2 week follow up appointment.
Time Frame
2 weeks postoperative
Title
Numeric Rating Scale of Pain
Description
It consists of 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme.
Time Frame
2, 6 and 12 weeks postoperative
Title
Oxford Knee score
Description
is a validated 12-item patient-reported outcome specifically designed and developed to assess function and pain after total knee replacement surgery. It scores from 0 (might indicate severe arthritis) to 48 (normal joint function).
Time Frame
6 and 12 weeks postoperative
Title
EQ-5D-5L
Description
It is a health-related quality of life measure that consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ-VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The EQ-VAS records the patient's self-rated health on a vertical visual analogue scale.
Time Frame
6 and 12 weeks postoperative
Title
Quality of Recovery
Description
The 15-item Quality of Recovery (QoR-15) scale is a validated, simple, reliable, multidimensional questionnaire that measures the quality of recovery after surgery. Fifteen questions assess five domains of patient-reported health status: pain, physical comfort, physical independence, psychological support and emotional state.
Time Frame
12 weeks postoperative
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male and female patients
18 to 80 years of age
Patients with radiographic confirmation and clinical correlation for severe osteoarthritis diagnosis with an indication for total knee replacement
Patients undergoing primary unilateral total knee replacement
No previous unilateral knee injection (steroids/biologics) within 6 months of study
The patient is able to read and understand English and provide informed consent to participation in the study
Exclusion Criteria:
Pregnancy and breastfeeding
Cryoglobulinemia
Paroxysmal cold hemoglobinuria
Cold urticaria
Raynaud's disease
Current Opioid use
History of opiate, narcotic and alcohol abuse
Revision total knee replacement surgery
Open and/or infected wounds at or near the affected knee
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Luana Melo
Phone
4168646060
Ext
77286
Email
luana.melo@unityhealth.to
First Name & Middle Initial & Last Name or Official Title & Degree
Amit Atrey
Phone
416- 864-5342
Email
amit.atrey@unityhealth.to
Facility Information:
Facility Name
St Michael's Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5B1W8
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amit Atrey, MD
First Name & Middle Initial & Last Name & Degree
Amit Atrey, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
26733654
Citation
Khan M, Osman K, Green G, Haddad FS. The epidemiology of failure in total knee arthroplasty: avoiding your next revision. Bone Joint J. 2016 Jan;98-B(1 Suppl A):105-12. doi: 10.1302/0301-620X.98B1.36293.
Results Reference
background
PubMed Identifier
26955608
Citation
Choi YJ, Ra HJ. Patient Satisfaction after Total Knee Arthroplasty. Knee Surg Relat Res. 2016 Mar;28(1):1-15. doi: 10.5792/ksrr.2016.28.1.1. Epub 2016 Feb 29.
Results Reference
background
PubMed Identifier
23575998
Citation
Hamilton DF, Lane JV, Gaston P, Patton JT, Macdonald D, Simpson AH, Howie CR. What determines patient satisfaction with surgery? A prospective cohort study of 4709 patients following total joint replacement. BMJ Open. 2013 Apr 9;3(4):e002525. doi: 10.1136/bmjopen-2012-002525. Print 2013.
Results Reference
background
PubMed Identifier
21239114
Citation
Wylde V, Hewlett S, Learmonth ID, Dieppe P. Persistent pain after joint replacement: prevalence, sensory qualities, and postoperative determinants. Pain. 2011 Mar;152(3):566-572. doi: 10.1016/j.pain.2010.11.023. Epub 2011 Jan 15.
Results Reference
background
PubMed Identifier
7477749
Citation
Zhou L, Kambin P, Casey KF, Bonner FJ, O'Brien E, Shao Z, Ou S. Mechanism research of cryoanalgesia. Neurol Res. 1995 Aug;17(4):307-11. doi: 10.1080/01616412.1995.11740333.
Results Reference
background
PubMed Identifier
12623025
Citation
Zhou L, Shao Z, Ou S. Cryoanalgesia: electrophysiology at different temperatures. Cryobiology. 2003 Feb;46(1):26-32. doi: 10.1016/s0011-2240(02)00160-8.
Results Reference
background
PubMed Identifier
28336454
Citation
Radnovich R, Scott D, Patel AT, Olson R, Dasa V, Segal N, Lane NE, Shrock K, Naranjo J, Darr K, Surowitz R, Choo J, Valadie A, Harrell R, Wei N, Metyas S. Cryoneurolysis to treat the pain and symptoms of knee osteoarthritis: a multicenter, randomized, double-blind, sham-controlled trial. Osteoarthritis Cartilage. 2017 Aug;25(8):1247-1256. doi: 10.1016/j.joca.2017.03.006. Epub 2017 Mar 20.
Results Reference
background
Learn more about this trial
Cryoneurolysis for TKA - a Pilot Study
We'll reach out to this number within 24 hrs